WHO ICTRP trial
A Phase II Study of Abatacept Versus Placebo to Assess the Prevention of…
ACTRN12605000785606 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Not Recruiting
Key facts
| Trial ID | ACTRN12605000785606 |
|---|---|
| Public title | A Phase II Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis (RA) in Adult Patients With Undifferentiated Arthritis Who Are at High Risk for the Development of RA |
| Scientific title | A Phase II Study of Abatacept Versus Placebo to Assess the Prevention of Rheumatoid Arthritis (RA) in Adult Patients With Undifferentiated Arthritis Who Are at High Risk for the Development of RA |
| Primary sponsor | Bristol-Myers Squibb Australia |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 2 |
| Countries | Australia |
| Conditions | Undifferentiated Arthritis (UA); Undifferentiated Arthritis (UA);Inflammatory and Immune System - Rheumatoid arthritis |
| Interventions | Drug: Abatacept for the first 6 months, then 18 months oberservation. Study Design: Educational/Counseling/Training, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
| Registration date | Sep 12, 2005 |
| Target size | 50 |
| Secondary IDs | Bristol Myers Squibb: IM101-046 |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: